Skip to content
StockMarketAgent
Direct answer
argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities. Fair value range: low $654, high $2709, with mid-point at $1486.
Stock analysis

ARGX fair value $654–$2,709

By StockMarketAgent.AI team· supervised by
विश्लेषित: 2026-05-20अगला अद्यतन: 2026-08-20Methodology v2.4Data cut-off: Quality gate: passSources: all material sources passed deterministic freshness/provenance gatesReview: automatedArchetype: Hyper-growth
View archive
मूल्य
$797.77
▲ +688.71 (+86.33%)
उचित मूल्य
$1486
$654–$2709
रेटिंग
मज़बूत ख़रीद
confidence 82/100
ऊपरी अंतर
+86.3%
upside to fair value
सुरक्षा मार्जिन
$1263.51
MoS level · 15%
बाज़ार पूंजीकरण
$49.9B
P/E fwd 21.8
अंग्रेज़ी फ़ॉलबैकHI
अनुवाद होने तक अंग्रेज़ी स्रोत दिखा रहा है
इस रिपोर्ट का अभी अनुवाद नहीं हुआ है। अनुवाद कतार पकड़ने पर कुछ मिनट में रिफ़्रेश करें।

§1 कार्यकारी सारांश

  • Commercial-stage status with visible traction in gMG/CIDP provides a reliable valuation floor.
  • Robust pipeline diversity reduces binary outcome risk compared to single-asset biotechs.
  • Forward earnings captures the massive earnings reset expected as assets reach peak penetration.
Fair value
$1,486
Margin of safety
+46.3%
Confidence
82/100
Moat
6.5/10

Educational analysis only — not financial advice. Always do your own due diligence.

$797.77Price
Low $654.18
Mid $1,486.48
High $2,709.48

argenx is a premier hyper-growth biotech firm transitioning to a commercial powerhouse. Its lead asset, VYVGART, is rapidly becoming the standard of care in generalized Myasthenia Gravis (gMG) and is successfully expanding into CIDP. The 'pipeline-in-a-product' strategy provides a long-duration growth profile with multiple multi-billion dollar indication opportunities.

  • IP-protected antibody platform
    IP-protected antibody platform
  • Pipeline-in-a-product strategy
    Pipeline-in-a-product strategy
  • Cycle upside
    High demand for specialized autoimmune therapeutic platforms.

§2 बेयर केस

In a sustained high-cost environment where CIDP expansion falters, valuation relies entirely on established gMG revenues.

इस थीसिस के टूटने के तरीक़े

FcRn Class Competition

· Medium

Next-generation competitors outcompete on pricing or efficacy, eroding market share.

FV impact
Severe

Secondary Indication Failures

· Low

Regulatory delays or clinical failures across 3+ secondary indications cap revenue.

FV impact
Moderate

Margin Compression

· Medium

Failure to cross 15% operating margins by FY2027 due to sustained high SG&A.

FV impact
Moderate
निगरानी हेतु शीघ्र चेतावनी संकेत
मेट्रिकवर्तमानट्रिगर सीमा
Operating margins failing to cross 15% by FY2027.MonitorDeterioration versus the report thesis
Regulatory rejection in secondary indications.MonitorDeterioration versus the report thesis
Clinical failure across more than 3 secondary indications.MonitorDeterioration versus the report thesis
Loss of market share in gMG to competitors.MonitorDeterioration versus the report thesis
Sustained increase in SG&A without revenue growth.MonitorDeterioration versus the report thesis

§3 वित्तीय इतिहास

आय विवरण — पिछले छह कालखंड
लाइन आइटमT−0T−1T−2T−3CAGR
अवधि2022-12-312023-12-312024-12-312025-12-31Trend
राजस्व$410.7M$1.23B$2.19B$4.15B+116.2%
सकल लाभ$381.3M$1.11B$1.96B$3.70B+113.3%
परिचालन आय$-723.9M$-420.6M$-17.8M$1.05B—
शुद्ध आय$-709.6M$-295.1M$833.0M$1.29B—
EPS (डाइल्यूटेड)$-13.05$-5.16$12.78$19.57—
EBITDA$-622.8M$-192.3M$105.2M$1.31B—
R&D$663.4M$859.5M$983.4M$1.36B+27.2%
SG&A$469.9M$709.5M$1.05B$1.36B+42.5%

गुणवत्ता स्कोर

OCF / शुद्ध आय
0.53×
>1 उच्च आय गुणवत्ता दर्शाता है
लेखा गुणवत्ता गेट
Fail
सेक्टर-समायोजित गेट
ROIC
13.8%
निवेशित पूँजी पर प्रतिफल
खंड 3

Numbers analysis

नकद प्रवाह

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

पूँजी आवंटन

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

व्यक्तिगत सब्सक्राइबर — §4 आगे11 और खंड

पूरा विश्लेषण पढ़ें — 11 और खंड.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

हर कवर किए गए टिकर के लिए पूर्ण रिपोर्ट
रेटिंग संग्रह के 24 महीने
वॉचलिस्ट ब्रीफ़िंग और रेटिंग-परिवर्तन अलर्ट
किसी भी भाषा में PDF + DOCX निर्यात
मुफ़्त ट्रायल शुरू करें
कभी भी रद्द करें।
INCOME STATEMENT FAQ

ARGX income statement questions

  1. Our financial-history view of ARGX (ARGX) covers revenue, gross profit, operating income, and net income across the past five fiscal years, with year-over-year growth and margin context for each line.

FAQ

ARGX — frequently asked questions

  1. Based on our latest analysis, ARGX looks meaningfully undervalued. The current price is $798 versus a composite fair-value midpoint of $1486 (range $654–$2709), which implies roughly 86.3% upside to the midpoint.

Related coverage

Names readers of ARGX also follow

Same archetype: hyper-growth